Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
MC2 Therapeutics
MC2 Therapeutics
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Wynzora
Betamethasone
,
Calcipotriene
2020-07-20
2027-2039
Psoriasis
,
Atopic dermatitis
,
Pruritus ani
,
Inflammation
,
Facial dermatoses
,
Seborrheic dermatitis
,
Foot dermatoses
,
Hand dermatoses
,
Scalp dermatoses
,
Leg dermatoses
,
Mycoses
,
Oral candidiasis
,
Vulvovaginal candidiasis
,
Tinea pedis
,
Cutaneous candidiasis
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Betamethasone
healthy volunteers/patients
Calcipotriene
healthy volunteers/patients
,
skin and connective tissue diseases
,
connective tissue diseases
,
eczema
,
atopic dermatitis
,
dermatitis
,
psoriasis
Betamethasone dipropionate
healthy volunteers/patients
,
eczema
,
atrophy
,
skin and connective tissue diseases
,
connective tissue diseases
,
psoriasis
,
atopic dermatitis
,
dermatitis
,
insulin resistance
Bos taurus adrenal cortex corticosteroids
libido
,
colorectal neoplasms
,
carcinoma
,
hepatocellular carcinoma
,
liver neoplasms
,
chronic renal insufficiency
,
kidney diseases
,
type 2 diabetes mellitus
,
diabetes mellitus
,
atopic dermatitis
,
dermatitis
Daivonex
psoriasis
,
follicular lymphoma
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use